公开(公告)号：US20240239790A1

公开(公告)日：2024-07-18

申请号：US18279379

申请日：2022-03-10

Applicant: adMare Therapeutics Society ,  LifeArc ,  Provincial Health Services Authority

Inventor： Stephen Paul Arns ,  Tom Han Hsiao Hsieh ,  Fahimeh S. Shidmoossavee ,  Jason Samuel Tan ,  Leanna Yee ,  Jay John Paquette ,  James Brian Jaquith ,  Simon Andrew Osborne ,  Ela Smiljanic-Hurley ,  Callum Hamby ,  Elliott Smyth ,  Martin Ambler ,  Andrew I. Minchinton ,  Alastair H. Kyle ,  Jennifer H.E. Baker

IPC: C07D471/04 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K45/06 ,  A61K48/00 ,  A61P35/00 ,  C07D519/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/63

CPC classification number: C07D471/04 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K45/06 ,  A61K48/005 ,  A61P35/00 ,  C07D519/00 ,  C12N9/22 ,  C12N15/111 ,  C12N15/63 ,  C12N2310/20

Abstract: The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)

公开(公告)号：US20240309070A1

公开(公告)日：2024-09-19

申请号：US18282507

申请日：2022-03-16

Applicant: ADMARE THERAPEUTICS SOCIETY ,  PROVINCIAL HEALTH SERVICES AUTHORITY ,  UVIC INDUSTRY PARTNERSHIPS INC.

Inventor： Emma J. Cummins ,  Jan Peter Bergqvist ,  Brad Nelson ,  Kwame Twumasi-Boateng ,  Yin Yu Eunice Kwok ,  Francois Benard ,  Julie Marie Rousseau ,  Kuo-Shyan Lin ,  Julian Smazynski ,  Sander Martinus Johannes van Duijnhoven

IPC: C07K16/08 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

CPC classification number: C07K16/081 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464838 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C12N5/0636 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/033 ,  C12N2510/00

Abstract: Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.

公开(公告)号：US20240246960A1

公开(公告)日：2024-07-25

申请号：US18279377

申请日：2022-03-10

Applicant: adMare Therapeutics Society ,  LifeArc ,  Provincial Health Services Authority

Inventor： Stephen Paul Arns ,  Tom Han Hsiao Hsieh ,  Fahimeh S. Shidmoossavee ,  Jason Samuel Tan ,  Leanna Yee ,  Jay John Paquette ,  James Brian Jaquith ,  Simon Andrew Osborne ,  Ela Smiljanic-Hurley ,  Callum Hamby ,  Elliott Smyth ,  Martin Ambler ,  Andrew I. Minchinton ,  Alastair H. Kyle ,  Jennifer H.E. Baker

IPC: C07D471/04 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D519/00 ,  C12N9/22 ,  C12N9/99 ,  C12N15/11

CPC classification number: C07D471/04 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D519/00 ,  C12N9/22 ,  C12N9/99 ,  C12N15/111 ,  C12N2310/20

Abstract: The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.

公开(公告)号：US20230027475A1

公开(公告)日：2023-01-26

申请号：US17642089

申请日：2020-09-11

Applicant: Admare Therapeutics Society ,  Provincial Health Services Authority ,  UVic Industry Partnerships Inc.

Inventor： Emma J. Cummins ,  Jan Peter Bergqvist ,  Brad Nelson ,  Kwame Twumasi-Boateng ,  Yin Yu Eunice Kwok ,  Julian Smazynski ,  Francois Benard ,  Julie Marie Rousseau ,  Kuo-Shyan Lin

IPC: C07K16/08 ,  A61P35/00 ,  A61K51/10 ,  C12N5/0783

Abstract: Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates, e.g., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.